Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1

Interventions

Specimen Handling 302Magnetic Resonance Spectroscopy 261pembrolizumab 249Carboplatin 184Cyclophosphamide 175Biopsy 167Cisplatin 157Gemcitabine 134Paclitaxel 130Bevacizumab 123fludarabine 115Nivolumab 108Radiotherapy 107Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 78Dexamethasone 76Pemetrexed 72Rituximab 69Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 64Doxorubicin 63Standard of Care 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Biopsy, Needle × 90 days × Clear all
NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡